The genetic basis of variation in drug response was investigated in individual Saccharomyces cerevisiae strains that exhibited different susceptibility to two antifungal agents: benomyl and ketoconazole. Following dose-response screening of 25 strains, 4 were selected on the basis of resistance or sensitivity relative to the standard laboratory strain BY. UWOPS87-2421 and L-1374 were respectively resistant and sensitive to benomyl; DBVPG6044 and Y12 were respectively resistant and sensitive to ketoconazole. We used advanced intercross lines and next generation sequencing-bulk segregant analysis to characterise the quantitative trait loci (QTL) underpinning drug responses after drug selection. Drug response was controlled by multiple QTL, ranging from a minimum of 5 to a maximum of 60 loci, almost all of which were not the primary drug target. For each drug, the resistant and the sensitive strain exhibited a number of shared loci, but also had strain-specific QTL. In our analysis, it was possible to estimate genetic effect of QTL, and a number of those shared between resistant and sensitive strains exhibited variable effect on the response phenotype. Thus, drug responses arise as a result of different genetic architectures, depending on the genetic background of the individual strain in question.
INTRODUCTION
The response to drugs (in terms of efficacy) often varies considerably between individuals (Davidson et al. 1997; Spear, HeathChiozzi and Huff 2001) , and their adverse reactions can also differ (Edwards and Aronson 2000) . In the medicinal field, this poses a significant healthcare problem, with over 100 000 annual cases of fatal drug reactions in the USA (Lu 1998; Lazarou, Pomeranz and Corey 1998; Pirmohamed and Park 2001; Spear, Heath-Chiozzi and Huff 2001; Wilke et al. 2007) . Programmes for bringing new drugs to market typically focus on a single cellular target; however, the fact that these programmes have high attrition rates as a result of inadequate efficacy or intolerable side effects suggests that such single target approaches may not be sufficient to ensure development of safe and effective drugs (Hopkins 2008; Schadt, Friend and Shaywitz 2009) . Thus, in order to achieve more effective treatment for patients, further study is warranted to identify risk factors that can lead to adverse drug reactions.
Differential drug responses, while being dependent on environmental factors and variations in metabolism, diet and general background health of the individual, also have a partial genetic basis. This is evidenced by heritability studies in twins (Vesell 1989 ) and the correlation of drug response with various mutations and polymorphisms in genes encoding drug targets and their functional pathways (Meyer 2000; Spear, HeathChiozzi and Huff 2001; Shastry 2005; Wilke et al. 2007 ). Response to drugs is known to vary between individuals on a genetic level, underpinning the field of pharmacogenetics/genomics (Nebert and Menon 2001; Meyer 2004; Antman, Weiss and Loscalzo 2012) . Most genetically controlled traits are quantitative, meaning they are influenced by multiple genetic loci (Hou et al. 2016) , and even traits that traditionally have been considered 'single gene traits' may be modified by additional loci (Cutting 2010) . The same principle holds true for the phenotype of drug response. Many highly effective drugs on the market today are known to exert their action through multiple cellular targets-contributing to a 'network pharmacology' or 'polypharmacology' (Imming, Sinning and Meyer 2006; Overington, Al-Lazikani and Hopkins 2006; Hopkins 2008; Keiser et al. 2009 ). To gain a full understanding of all the genetic factors important for individual variation in drug response, drug-resistant or sensitive phenotypes must be studied in a way that can identify all such variants at once in an unbiased genome-wide manner. Quantitative trait locus (QTL) mapping is one such approach (Mackay, Stone and Ayroles 2009) .
The budding yeast Saccharomyces cerevisiae with its small, exon-rich genome (Sherman 2002 ) is particularly suited for genomic work such as QTL mapping. Furthermore, it has been adapted for specialised techniques such as bulk segregant analysis (BSA) (Michelmore, Paran and Kesseli 1991 )-a powerful technique that identifies causative alleles by their difference in frequency between two populations of different phenotypes. A particularly valuable modification to BSA has been the application of next-generation sequencing (NGS) to establish a method known as NGS-BSA (Ehrenreich et al. 2010) . Here, the total genomic DNA of a population is subjected to whole genome sequencing, allowing large mapping populations of thousands or millions of individual cells to be simultaneously and economically genotyped. This approach enables discovery of a greatly increased number of QTL than would be possible using classical individual segregant analysis (Ehrenreich et al. 2010; Parts et al. 2011; Cubillos et al. 2013) . Additionally, the use of advanced intercross lines (AILs) reduces linkage disequilibrium between genomic markers, narrowing the QTL intervals under investigation (Darvasi and Soller 1995) and increasing genetic map distances for greater resolution. AILs have been successfully combined with NGS-BSA to refine QTL intervals (Parts et al. 2011) .
The Saccharomyces Genome Resequencing Project (SGRP) ) is a valuable source of yeast strains with known genomic variation. These strains have been modified through the introduction of a ho null deletion to make them heterothallic (having opposite mating types that reside in different individuals) and thus amenable to genetic studies (Cubillos, Louis and Liti 2009 ). In the current study, natural isolate yeast strains from the SGRP collection were used as a proxy for human individuals to study drug response (Dowell et al. 2010) . Yeast have been successfully used to map QTL involved in responses to drug and bioactive compounds (Perlstein et al. 2007; Ehrenreich, Gerke and Kruglyak 2009; Ehrenreich et al. 2010; Bloom et al. 2013 ). Many of these earlier studies have used a cross between the RM-11 wine strain and the BY laboratory strain; however, other studies using more diverse genetic backgrounds have provided even more useful information. This is because sampling from a broader range of segregating genetic loci reveals a wider range of QTL, even identifying novel QTL that were not found in previous investigations of the same test compounds (Kim and Fay 2007; Kim and Fay 2009; Cubillos et al. 2011; Ehrenreich et al. 2012) .
Two antifungal agents, benomyl and ketoconazole, which both have known molecular targets, were used in this study. Benomyl is a microtubule depolymerising agent that binds to β-tubulin (encoded in S. cerevisiae by the gene TUB2) (Davidse 1986 ) and affects movement of chromosomes and the nuclear envelope in cell division (Stearns 1990; Winsor and Schiebel 1997) . Benomyl interferes with a number of cellular processes that involve microtubules (Delgado and Conde 1984; Hardwick and Murray 1995; Hoyt et al. 1997; Fujiwara et al. 1999 ) and leads to mitotic block, aberrant exit from mitosis and eventual apoptotic destruction (Thomas, Neff and Botstein 1985; Davidse 1986; Jordan and Wilson 2004; Rathinasamy and Panda 2006) . Ketoconazole interferes with the 14-α-demethylation of lanosterol in the ergosterol biosynthesis pathway (Lupetti et al. 2002; Kathiravan et al. 2012) by inhibiting the activity of cytochrome P450 lanosterol 14 α-demethylase (encoded by ERG11 in yeast). The growth-inhibitory activity of ketoconazole results from depletion of the ergosterol end product and the build-up of ergosterol pathway intermediates and their conversion to toxic species, such as 14α-methyl-3,6-diol and toxic ketosteroids (Lamb, Kelly and Kelly 1999; Marichal et al. 1999; Lupetti et al. 2002; Kathiravan et al. 2012) . Benomyl and ketoconazole were used in this study because their primary cellular targets are well characterised, allowing identification of off-target and individual strain-specific loci that determine strain-specific differential responses.
The aim of this study was to investigate whether individual strains of the SGRP collection exhibit a differential response to either drug (benomyl or ketoconazole) and, if so, what the genetic basis of this differential response is. We used whole genome sequencing in budding yeast to study individual variation at high resolution through the use of AILs and NGS-BSA.
METHODS

Compounds and media
Benomyl was purchased from Sigma Aldrich NZ Limited (Auckland, New Zealand). Ketoconazole was purchased from Jinlan Pharm-Drugs Technology Co. Ltd (Hangzhou, China). Hygromycin B (HygB) was purchased from InvivoGen Inc. (San Diego, CA, USA), and nourseothricin (clonNAT) was purchased from Werner BioAgents (Jena, Germany). All compounds were dissolved in DMSO (Sigma Aldrich) apart from HygB and clon-NAT, which were dissolved in distilled deionised water (dH 2 O). All drug treatment experiments were performed in synthetic complete (SC) medium in agar. For benomyl treatment, the SC medium was supplemented with 25 mM pH 8.0 HEPES. Mating was performed on yeast peptone dextrose (YPD) medium in agar. Diploid selection was performed on YPD in agar supplemented with HygB (400 μg/mL) and clonNAT (100 μg/mL). Sporulation was carried out in liquid format in enriched sporulation medium. All media recipes and culture conditions follow standard protocols (Amberg, Burke and Strathern 2005) .
The yeast strains used are described in Table 1 . The strains BY4741 and BY4742 were derived from a deletion mutant array purchased from Open Biosystems (GE Healthcare Life Sciences, Auckland, New Zealand) and modified by marker switch to contain a NatMX4 resistance cassette in place of an HO open 
Dose-response testing of SGRP collection
The MATa haploid SGRP collection and the BY4741 control strain were treated with a range of concentrations of benomyl (0-500 μM) or ketoconazole (0-350 μM). Strains were arrayed in 384-colony format using a Singer RoToR HDA pinning robot (Singer Instruments Co. Ltd., Somerset, UK) and pinned onto plates containing the drugs. Following 72 h incubation at 30
• C, the plates were photographed, and colony size was measured using Gitter software (Wagih and Parts 2014) . Residual growth was calculated for each colony using the following formula:
Residual growth (%) = Colony size treated Colony size untreated × 100
The dose-response was carried out in triplicate for each compound of interest. The maximal inhibitory concentrations (IC 100 ; concentration above which there is no further reduction in growth) of drugs against the SGRP collection were compared in order to identify the most resistant and the most sensitive strains.
Creation of AILs
Following identification of a resistant and sensitive strain for each of the two drugs, four individual AILs were created by individually intercrossing each of the four strains with the control BY strain. For each AIL, the two strains were mated, diploids were selected and sporulation was performed according to standard protocols. Following sporulation, a minimum of 2.5 × 10 8 tetrads were collected, washed with dH 2 O and submitted to a treatment that destroys vegetative cells. For this, the sporulated cultures were pelleted and the cells were resuspended in 100 mM Tris (buffered with HCl to pH 9.4) containing 10 mM DTT and incubated in a 30
• C water bath for 10 min. The cells were then resuspended after pelleting in 0.5 mg zymolyase in 1 mL of 2.1 M sorbitol, 10 mM NaH 2 PO 4 (pH 7.2) and incubated at 30
• C for 5 h. The cells were pelleted and resuspended in 0.4% w/v SDS containing 1 mM DTT and sonicated in four 30-s periods (with 1 min incubation on ice between each sonication). Additional SDS was added to a final concentration of 1%, and the cells were incubated at 37
• C for 1 h and then at 55
• C for 10 min. The cells were resuspended in YPD and plated on YPD in agar for another round of mating and diploid selection. A minimum of 1.5 × 10 8 diploids were inoculated for the next round of sporulation. The intercross process was repeated a total of 10 times, after which no appreciable improvement in the refinement of the QTL interval occurs (Darvasi and Soller 1995) .
Optimisation of drug treatment format for pooled AIL segregant progeny
Drug treatment of the AIL progeny involved treating large numbers of individual segregants, which was most easily achieved by growing cells as a lawn on agar plates that contained the drug of interest. Because this was a different format to the way the SGRP strains were identified for study, the original parental strains that were used for construction of the AILs were re-tested in this format to ensure that the expected drug response phenotype was maintained and to select the drug treatment dose for the final NGS-BSA experiment.
As the AIL segregant progeny used in the final experiment were diploid, these forms of the parental strains (Table 1) were used for re-testing in the new format. Each parental strain was grown in 20 mL of SC medium overnight at 30
• C in a shaking incubator set at 200 rpm. Following growth, cells were diluted to a concentration of 1 × 10 5 cells/mL using dH 2 O. A series of SC agar plates were prepared containing increasing concentrations of the drug of interest and 1 mL of vortexed cell suspension was spread over the surface of the agar in the plate using a sterile L-shaped glass rod. After the cell suspension had fully absorbed onto the agar, the plates were incubated at 30
• C for 72 h. The cells were then collected from the diploid selection plate by pipetting 1 mL of dH 2 O onto the surface of the agar, suspending the cells in liquid by gently scraping the surface with a sterile L-shaped glass rod, and then collecting the cell suspension by pipette and transferring it to a sterile 15 mL centrifuge tube. This process was repeated two to three times until no cells remained on the agar. The volume in the tube was then made up to 10 mL with dH 2 O, and growth was quantified by cell counting in a haemocytometer. The dose-response was carried out in triplicate for each drug of interest. The dose-response curves were used to determine the appropriate concentration of drug with which to treat the AIL segregant progeny namely that which was completely inhibitory to the more sensitive parent in each cross. This allowed the most resistant progeny in each AIL population to be selected. Because sensitivity is not a selectable phenotype, this protocol selected the most drug-resistant segregants in the crosses of the sensitive SGRP strains with BY. The difference in the growth of the parental strains at the selected drug concentration was tested for significance using an unpaired Student's t-test (at a significance level of 0.05).
Selection of meiotic segregants with desired drug response phenotypes
A minimum of 1 × 10 5 AIL individual diploid segregants were grown overnight in SC medium at 30
• C. The cells were diluted to 1 × 10 5 cells/mL and plated on SC agar plates containing the concentrations of benomyl or ketoconazole selected as described in the previous section. The cells were incubated at 30
• C for 72 h, after which they were collected from the surface of the agar using a sterile L-shaped glass rod and a pipette and the cell numbers determined by counting in a haemocytometer.
DNA extraction, library preparation and sequencing
Genomic DNA was extracted using phenol-chloroform coupled with ethanol precipitation and RNase A treatment. For the NGS-BSA experiment, equal samples of gDNA were extracted for the control and the drug-treated segregant populations for each AIL. Truseq Nano 350 bp insert libraries were prepared at Macrogen, South Korea. The BY4742 and L-1374 parental strains were sequenced using a 1 Gb package offered by the sequencing provider using an Illumina HiSeq2000 (2 × 101 bp reads) that resulted in ∼×100 coverage. Base calling was performed using the Illumina Pipeline (CASAVA) v1. 
Download of external data
Read data were obtained for three strains from previously published work: DBVPG6044 (SRA number SRR1568151; Song et al. 2015) , UWOPS87-2421 (SRA number ERR049930; Bergström et al. 2014) and Y12 (SRA number SRR800842; Strope et al. 2015) .
Public data availability
Raw sequence data for the strains BY4742, L-1374 and the eight sequenced AIL segregant populations (drug-treated and control populations for DBVPG6044 × BY AIL, L-1374 × BY AIL, UWOPS87-2421 × BY AIL and Y12 × BY AIL) are all publicly available at SRA: SRP103440 and BioProject: PRJNA382253. 2017) ). Base quality score recalibration was performed with the GATK, with known S. cerevisiae variants from SGD and Ensembl (Cunningham et al. 2015) . The SAMtools 'view' command was used to filter the binary sequence alignment/map (BAM) file to eliminate unmapped, non-unique or poorly mapped reads (using '-f 0 × 0.0002', '-F 0 × 0004' and '-F 0 × 0008' options), and '-q 30' removed any reads with a low mapping quality.
Alignment to reference genome
Genotyping of parental strains
Following alignment to the S288C reference, the parental strains underwent variant calling to obtain high-quality SNPs that could be used as genomic markers. The 'mpileup' command of SAMtools with the '-uf' options converted the BAM to binary variant call format (BCF), using the BCFtools v1.2-74-g6ccecd1+ 'view' command with options '-cgvi "MIN(DP)> = 15 && MIN(QUAL)> = 30"'. The variant file was manually filtered to contain only SNPs and exclude indels. These genomic markers were biallelic and were further filtered to only include identical SNP sites between the two parents used in the cross, as described in the next section.
Analysis of segregant sequence data
The sequence data from the AIL segregant population underwent the same alignment to the S288C reference genome described in the section 'Alignment to reference genome'. Following the filtration, the BAM file was converted to pileup format using SAMtools 'mpileup' ('-f' option). The pileup was converted to a sync file with the mpileup2sync Perl script of Popoolation2 v1201 (Kofler, Pandey and Schlötterer 2011 ). The sync file was then manually converted to a 'count file' for each chromosome that contained the allelic counts at each variant position from each of the two parents that were used to construct each AIL (the BY parent and the DBVPG6044, L-1374, UWOPS87-2421 or the Y12 parent, respectively). The '-thin' command of VCFtools v0.1.13 (Danecek et al. 2011 ) was used to eliminate any SNPs that were less than 125 bp apart to ensure SNPs originated from independent reads. The count file was also manually edited to eliminate any positions where the allele frequency of either parent was <0.1 or >0.9, or that were covered by fewer than 15 reads. The count files for the control segregant population and the drugtreated population were edited to contain matching SNP sites. MULTIPOOL v0.10.2 (Edwards and Gifford 2012) was used to identify genomic regions that showed significant differences in allele frequency between the control and the drug-treated segregant populations. The count files described above formed the input, and MULTIPOOL was run in 'contrast' mode with the options of '-c 1500' (1500 bp per centiMorgan) and '-n 10000' (pool size of 10 000 segregants). The actual segregant population pool size was ∼100 000, but a 10-fold reduction from the actual estimated pool size in the segregant population was introduced to account for the fact that not all segregants would be represented in the final population.
QTL calling
For each sample, the LOD scores over the entire genome were converted to p-values (Nyholt 2000) , and a Benjamini and Hochberg false discovery rate was determined at a significance level of 0.0001, normally corresponding to an LOD score of ∼3. MULTIPOOL produces its LOD estimates over 100 bp genomic bins, and the number of trials was set as the number of genomic bins output by MULTIPOOL. The adjusted p-value from this calculation was converted to a LOD score, and this was used as a significance threshold for that sample. Individual QTL were named based on their non-BY parental strains (UWOPS, L-1374, DBVPG and Y12), the chromosome number and the start position of the QTL interval.
The LOD scores were plotted against chromosomal position across the entire genome. The centre of the QTL was deemed to be the inflection point of the LOD graph (i.e. the peak). In situations where two or more genomic bins had the same maximal LOD score, the centre of the QTL was considered to be the midpoint of the genomic region encompassing the multiple bins. Furthermore, the interval of the QTL was determined to be the region that lies within three LOD scores of the QTL peak, as done by Cubillos et al. (2013) . QTL were not called within subtelomeres (within 30 kb of chromosome ends) due to the low sequencing coverage that tends to be observed in those regions (Parts et al. 2011) .
Analysis of the genetic architecture of drug response in different genetic backgrounds
To compare QTL between samples, two QTL peaks were considered identical if the two QTL intervals under consideration fell within 10 kb of each other (Cubillos et al. 2013) . QTL peaks within each cross were ranked on the basis of their LOD score height (which is a function of differences in allele frequency between the control and the drug-treated population). In order to make the LOD scores more comparable between samples, the maximum LOD score of each QTL peak was normalised by expressing it as a percentage of the tallest QTL peak on that graph.
RESULTS
Dose-response testing of the SGRP collection and selection of drug response strains
A panel of 25 strains from the SGRP collection was tested against benomyl and ketoconazole. Particular resistant and sensitive strains for each drug (four strains in total) were selected on the basis of their maximal inhibitory concentration for further characterisation by NGS-BSA.
The SGRP collection tested against benomyl displayed a continuum of susceptibility to this drug in terms of IC 100 (Fig. 1) . This suggested the benomyl response is underpinned by multiple genomic variants, since a single causative variant would more likely produce a bimodal distribution of response (Hou et al. 2016) . The BY control strain had a benomyl IC 100 of 300 μM whereas the most resistant strain, UWOPS87-2421 (isolated from a cladode of Opuntia megacantha), was not completely growth inhibited at the highest benomyl dose tested (500 μM). This strain was selected as the benomyl resistant strain for further study. The growth of strain L-1374 (isolated from must of Pais grapes) was completely inhibited at 200 μM, and this strain was selected as the sensitive strain. Three other strains that exhibited even greater benomyl sensitivity than L-1374 could not be used because one (YIIc 17 E5) did not form viable offspring with the control BY strain, another (W303) failed to grow on hygromycin B selection medium suggesting a problem with the ho ::HphMX4 construct and the third (BC187) did not exhibit a consistently sensitive phenotype to benomyl (data not shown).
A similar continuum of susceptibility was observed in the SGRP collection in response to ketoconazole (Fig. 2) . In this instance, the BY control reached its IC 100 at 160 μM ketoconazole.
The strain DBVPG6044 (from bili wine from Osbeckia grandiflora) was chosen as the candidate ketoconazole-resistant strain, as it did not achieve complete growth inhibition at the highest dose of ketoconazole tested (350 μM). The other two strains that displayed equivalent levels of resistance to ketoconazole could not be used: one (YIIc 17 E5) for the aforementioned reasons of infertility with BY and the other (NCYC110) because it had low overall viability and displayed unusual growth characteristics, forming colonies of highly variable size (data not shown). Of the strains that were ketoconazole sensitive in relation to the BY control, UWOPS03-461.4, UWOPS05-217.3, UWOPS05-227.2 and UWOPS83-787.3 failed to form viable offspring with the BY control strain; W303 failed to grow on hygromycin B selection medium; 273614N did not maintain a consistently sensitive phenotype to ketoconazole (data not shown). Therefore, Y12 (an African palm wine strain), which reached complete growth inhibition at 100 μM ketoconazole, was selected as the candidate ketoconazole-sensitive strain for further study. To enhance the resolution of the selected mapping procedure, AILs were created from each of the four selected candidate strains by performing 10 random intercrosses of each strain with the BY control laboratory strain.
Optimisation of drug treatment format for pooled AIL segregant progeny
The four selected SGRP strains were tested for dose-response in a modified drug treatment format (as described in Methods) to establish treatment concentrations under these conditions (Figs 3 and 4) . The selected doses for treatment of the segregant AIL population crosses, based on these results, were UWOPS872421 × BY AIL 80 μM benomyl; L-1374 × BY AIL 50 μM benomyl; DBVPG6044 × BY AIL 65 μM ketoconazole; Y12 × BY AIL 15 μM ketoconazole.
NGS-BSA to characterise the genetic architecture underlying drug response phenotypes
An unbiased genome-wide approach was used to define the genetic basis of individual strain variation contributing to off-target effects of the two drugs. NGS-BSA was thus used to map the responsible QTL in all four AILs. This technique depends on the principle that a mapping population carries a certain distribution of the two parental alleles. Following drug treatment (when comparing against an untreated population), the relative frequency of the alleles will change, as the parental allele that helps cells survive becomes more frequent in the treated population. MULTIPOOL incorporates information about allele frequency differences between the control and drugtreated populations with marker linkage information and data noise levels. The QTL scans reported here plot LOD score against chromosomal base-pair position of the QTL where the LOD reflects the probability of finding a QTL at a particular locus (as a result of a likelihood ratio test for a model which assumes the presence of a QTL at a particular location versus a model without a QTL). Classically, that probability depends on the magnitude of the genetic effect (i.e. the phenotype difference between the two parental genotypes) and the distance from the nearest markers used to locate the QTL. In the current study, distance to a marker is a negligible factor due to the high frequency of the markers. LOD scores produced by MULTIPOOL in 'contrast' mode are a reflection of allele frequency differences between the control and the drug-treated population (Edwards 2013) . While estimated allele frequencies can be confounded by a number of factors, such as sampling noise and bias during sample preparation (Edwards and Gifford 2012) , such factors were kept uniform between all the samples, as they were all treated, sequenced and analysed simultaneously and in the same manner. We thus reasoned that differences in allele frequency (and consequently, LOD score) chiefly reflect the magnitude of effect that a genetic locus has on the phenotype-a conclusion illustrated by previous NGS-BSA studies (Duveau et al. 2014 ). This reasoning is supported by the co-occurrence of difference in allele frequencies of the drug-treated and the control mapping populations at particular chromosomal locations and the differences in the calculated LOD score at those points, as seen in Fig. 5 .
The outcome of the NGS-BSA analysis with each of the four candidate AIL strains confirmed that multiple genetic loci underpinned the specific drug-response phenotype of each individual strain. The full list of QTL intervals is provided in Tables S1-S4 (Supporting Information). The UWOPS87-2421 × BY cross revealed 18 QTL in response to benomyl treatment (80 μM) of the AIL. The L-1374 × BY cross revealed five QTL in response to 50 μM benomyl treatment. Four of the QTL were shared between the two crosses. Fourteen QTL were unique to the UWOPS87-2421 × BY cross, whereas one QTL was specific to the L-1374 × BY cross. The QTL involved in response to benomyl are presented in Fig. 6 . The four QTL that were shared between the UWOPS87-2421 × BY cross and the L-1374 × BY cross are denoted by black arrowheads.
QTL for ketoconazole response also showed a mixture of shared and cross-specific loci, similarly to that seen in the benomyl response. The DBVPG6044 × BY cross revealed 10 QTL in response to treatment with 65 μM ketoconazole (at which the relatively sensitive BY strain in the cross was completely growth inhibited). The Y12 × BY cross revealed 60 QTL involved in response to 15 μM ketoconazole. Seven of these QTL were shared between the two crosses, whereas three of the QTL were unique to the DBVPG6044 × BY cross, with 53 specific to the Y12 × BY cross. The QTL involved in response to ketoconazole are presented in Fig. 7 . The QTL that are shared between the DB-VPG6044 × BY cross and the Y12 × BY cross are denoted by black arrowheads.
The QTL that were shared between the resistant cross and the sensitive cross are detailed further in Tables 2 and 3 . For benomyl response, the QTL on chromosomes XIV and XV had Table 2 ). However, those two QTL likely had a greater effect on the benomyl response phenotype in the UWOPS87-2421 × BY cross than in the L-1374 × BY cross, as evidenced by higher LOD scores and normalised peak height scores. The QTL on chromosomes I and V showed striking differences in terms of height rankings; these two QTL were the third and fourth highest peaks in the L-1374 × BY cross, but were only the ninth and seventh highest peaks in the UWOPS87-2421 × BY cross.
For ketoconazole response, the shared QTL on chromosome IV showed similar height rankings in the DBVPG6044 × BY and the Y12 × BY crosses. However, there were also a number of striking contrasts within other shared QTL. The first QTL on chromosome II had the strongest effect on the benomyl response phenotype in the Y12 × BY cross (ranked first) yet had the weakest effect on the phenotype in the DBVPG6044 × BY cross (as it had the lowest rank in that cross, with a normalised height of 26%). Conversely, the second QTL on chromosome II had the greatest effect on the benomyl response phenotype in the DBVPG6044 × BY cross, but not in the Y12 × BY cross, where it was the seventh highest peak, with a normalised peak height of only 16%. These observations show that while the same QTL can be found in different crosses, their genetic effect may differ depending on the genetic background of the strains involved in the cross.
DISCUSSION
This study provided detailed insight into the genetic basis of individual variation in drug response, as modelled with natural isolate strains of Saccharomyces cerevisiae. Drug response was found to be a complex trait with contributions from multiple QTL, despite the fact that each of the drugs used in this studynamely benomyl and ketoconazole-has a single primary target (Davidse 1986; Lupetti et al. 2002) . In fact, only one of the 92 QTL reported here, 12.VIII.116400 QTL, was found to contain the primary target of the drug. This QTL subtended ERG11-the gene that encodes the primary target of ketoconazole. However, even 'Normalised peak height' describes the height of the particular QTL peak (in terms of LOD score) as a percentage of the tallest QTL peak in that cross. 'Rank by peak height' refers to the order of height (by LOD score) of QTL peaks in the cross. then, this QTL was only ranked as the ninth highest peak in the Y12 × BY cross and had a fairly minor effect on the ketoconazole response phenotype. Thus, the vast majority of the variable drug response between individual yeast strains in this study arose as a result of off-target effects. This observation suggests that drug response can be significantly affected by off-target factors (even when there is a primary drug target)-a consideration that should be taken into account when detailed drug mechanisms are sought to maximise drug efficacy. There was considerable individual-specific variation that contributed to drug response. This is evidenced by the fact that a number of cross-specific peaks were found (i.e. peaks that were found in one cross used for examining response to either benomyl or ketoconazole, but not the other cross; listed in Tables S1-S4). It was striking that the two peaks with the strongest genetic effect in the benomyl response were cross-specific (these being UWOPS.XV.637200 and L-1374.V.156800). Furthermore, even when QTL peaks were shared between the resistant and the sensitive strain, they often exhibited variable genetic effect, in terms of LOD score, as detailed above. We conclude from this that even when the resistant and the sensitive strain exhibit an overlap of their genetic architecture, these shared QTL may make different contributions to the drug response phenotype in their respective strains.
From our results, we conclude that a phenotype (such as drug response) can arise as a result of different genetic underpinnings, depending on the genetic background of the individual strains used in the cross, a conclusion that is supported in other studies. Heterogeneity in the genetic foundations of a phenotype has been observed previously (Taylor and Ehrenreich 2014; Taylor et al. 2016) . In one study, a causative quantitative trait nucleotide (QTN) was found to be effective only in some strains exhibiting the same phenotype (Deutschbauer and Davis 2005) . Variable genetic underpinnings of particular phenotypes have also been reported in which alternate QTL arose to deal with the same stressor (alkali stress) (Romano et al. 2010) . Furthermore, when comparing the contribution of the alleles from multiple strains to a single phenotype, it has been shown that most cases of the contribution to phenotype are made by alleles that are private to one strain (an occurrence called 'allelic singletons') (Ehrenreich et al. 2012; Cubillos et al. 2013) .
Some of the QTL found in our study for benomyl and ketoconazole response showed a confirmatory overlap with the literature (Ehrenreich et al. 2012) . Ehrenreich et al. found a total of 26 QTL that contributed to benomyl response when comparing four genetic backgrounds. Two of their QTL are likely to overlap with QTL found in the UWOPS87-2421 × BY cross in our study (Table 4 ). An additional five QTL in the Ehrenreich study were located near the benomyl response QTL in our study (i.e. within 50 kb). In a different study, Perlstein et al. (2007) reported a QTL for ketoconazole response in the vicinity of the gene SWH1 on Chr. I. This is likely to correspond to the Chr. I QTL (position 204 200-226 400) found in this study for ketoconazole in the Y12 × BY cross, a QTL that we did not report in this study as it was subtelomeric.
In addition to previously discovered QTL, our study also uncovered a large number of novel QTL that contributed to either benomyl or ketoconazole response. This study is the first application of NGS-BSA to characterise response to ketoconazole, and all the QTL reported here have not been previously linked to this phenotype. This likely reflects the fact that NGS-BSA allowed us to use large mapping populations (on the order of 10 5 segregants), thus providing additional power compared to the individual segregant analysis used in previous studies. Furthermore, the genetic backgrounds employed here for the NGS-BSA have not been explored in previous QTL studies. Different genetic backgrounds have different genetic variants segregating between them and may uncover a different set of contributing loci to a phenotype in question. The fact that our study found an additional 12 benomyl response QTL compared to a similarly powered NGS-BSA study (Ehrenreich et al. 2012) supports the fact that the phenotypic diversity-driven approach is a good approach for finding a rich variety of QTL. The use of AILs has been advantageous for enhancing the localisation power of QTL studies in previous work (Parts et al. 2011; Cubillos et al. 2013 ). Cubillos et al. estimated that their fourparent AILs should have reduced the 3-LOD QTL interval size from 64 kb in F1 to 6 kb in F12. However, the actual median QTL interval observed in their study was 27.8 kb, which they explained by possible linkage between QTL peaks resulting in a wider variance in the observed peak, or alternatively, from a non-uniform recombination. These factors are likely to apply to our study as well, in which a 3-LOD QTL gave an estimated median interval of 43 kb. Different design between our study and others that have applied AILs (such as the lack of application of a prolonged phenotypic selection) may have contributed to the relatively large QTL interval found here. Nevertheless, this 43-kb interval still presents a reduction of the predicted 64-kb F1 interval estimated by Cubillos et al. and indicates that the AIL procedure improves the QTL resolution.
We conclude from our study that individual-specific drug response can vary widely, and we offer preliminary information as to where the causal genetic variants for this response may be found. The QTL reported here contained a median of 21 genes and high number of SNPs and indel variants, and further investigation is needed to establish which of these variants are causal to the phenotype (the causative QTN). A number of techniques such as reciprocal hemizygocity analysis, allele swapping or site-directed mutagenesis can be applied to achieve this aim (Liti and Louis 2012) . Though only a single replicate of the NGS-BSA procedure was performed here, we recapitulated QTL that had been previously reported in the literature for benomyl response, suggesting the procedure was nevertheless able to capture true QTL. One other caveat is that the 'shared' QTL in our study may have heterogeneous genetic underpinnings. As their causative QTN are yet to be elucidated, it cannot be established whether they are identical in the shared QTL. A previous study has shown that a single QTL interval may come about as a result of different causative genetic variants, depending on its genetic background of origin (Linder et al. 2016) . Even if this was the case in the current study, this would still support the conclusion that drug response arises as a result of different sets of QTL.
The findings of this study have practical application in the clinical setting as they provide insight into potential causes of antifungal resistance. Increasing resistance to existing antifungals is a growing problem, exacerbated by a lag in the development of novel agents (Kanafani and Perfect 2008; Denning and Bromley 2015) . The identification of off-target QTL that contribute to drug response in yeast could highlight the potential use of combination therapy to improve outcome in cases of drug-resistant fungal infections (Baddley and Pappas 2005; Johnson and Perfect 2007) . In addition (and as a more general note), these results indicate that individual variation in terms of genetic background can have a significant effect on treatment outcome. Therefore, single-target assumptions regarding the effect of drug treatment may be inadequate to achieve optimal outcome, and a genomic style treatment approach may present a better alternative (Keith, Borisy and Stockwell 2005; Hopkins 2008 ).
